CJC-1295: Research, Mechanism, Regulatory Context

Research overview

Growth hormone-releasing hormone (GHRH) is a 44-amino-acid hypothalamic peptide that stimulates the anterior pituitary to produce and secrete growth hormone. Native GHRH has a very short active half-life of just a few minutes in circulation due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and clearance by the kidneys. Pharmaceutical research into GHRH analogs has therefore focused substantially on extending duration of action — a goal that CJC-1295 achieves through a distinctive albumin-binding strategy.

CJC-1295 was identified through systematic synthesis of maleimido derivatives of hGRF(1-29) — a biologically active 29-amino-acid fragment of GHRH — and bioconjugated variants were screened for albumin binding and GH-releasing activity. The selected compound features the native GHRH(1-29) sequence with four amino acid substitutions (to improve stability and receptor affinity) and an added N-epsilon-3-maleimidopropionamide derivative of lysine at the C-terminus. After subcutaneous injection, this reactive group forms a covalent bond with cysteine-34 on serum albumin, co-opting albumin's natural long circulatory half-life (approximately 19 days in humans) to protect the peptide from degradation.

The pharmacodynamic consequences of this extended half-life are substantial in animal research. Rat studies demonstrated that CJC-1295 produced a four-fold increase in GH area under the curve compared to native hGRF(1-29), with measurable plasma levels persisting beyond 72 hours. Human Phase 1 and Phase 2 research conducted during early clinical development reported that a single injection of CJC-1295 produced 2-to-10-fold increases in mean plasma GH concentrations sustained for six or more days, and 1.5-to-3-fold elevations in IGF-1 lasting nine to eleven days. Importantly, these GH elevations appeared to preserve the pulsatile pattern of GH secretion — a physiologically relevant feature, since pulsatility is important for many of growth hormone's downstream anabolic and metabolic effects.

CJC-1295 is frequently referenced in conjunction with ipamorelin in research and clinical wellness contexts. The rationale for combination use is mechanistic: CJC-1295 (a GHRH analog) stimulates GH secretion via the GHRH receptor, increasing pulse amplitude, while ipamorelin (a GHRP/ghrelin receptor agonist) triggers GH release through a distinct, additive pathway. Preclinical and research data suggest these mechanisms can act synergistically, though controlled human clinical trials examining the combination remain limited. CJC-1295 was never advanced to Phase 3 clinical trials by its original developers, and no pharmaceutical product based on the compound has received regulatory approval.

Mechanism, in plain language

CJC-1295 binds and activates the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells — the same receptor targeted by endogenous growth hormone-releasing hormone. This receptor activation drives transcription and secretion of growth hormone stored in somatotroph secretory granules, and also stimulates pituitary GH gene expression over longer time frames. What distinguishes CJC-1295 from native GHRH is the Drug Affinity Complex (DAC) modification: a reactive maleimide group on the peptide's C-terminus reacts with cysteine-34 of serum albumin in the bloodstream, forming a stable covalent conjugate. Because albumin has a circulatory half-life of roughly 19 days, the conjugated peptide is protected from enzymatic degradation and renal clearance, allowing sustained receptor stimulation over days rather than minutes. The resulting GH elevation preserves pulsatile secretion patterns rather than producing the tonic, non-pulsatile GH exposure seen with direct exogenous GH administration.

What has been studied

GH and IGF-1 elevation pharmacodynamics in human Phase 1/2 research (single-dose escalation)
Normalization of growth and body composition in GHRH-knockout mouse models
Anti-doping detection methodology in equine plasma (sports regulation context)
Albumin bioconjugation and half-life extension as a drug delivery strategy
Combination GH secretagogue protocols in research settings (paired with ipamorelin)

Regulatory context

CJC-1295 has not received FDA approval for any indication and was not advanced beyond early clinical development by its original pharmaceutical developers. It does not appear on the FDA's list of bulk substances approved for compounding under 503A or 503B, placing it in the same unresolved regulatory space as most unapproved peptide compounds. The FDA's enforcement focus on compounded peptides has increased since 2023, and providers offering CJC-1295 in clinical or wellness settings should assess current guidance carefully. CJC-1295 is detectable in drug testing matrices developed for anti-doping purposes, and immunoassay-based detection methods have been published in the scientific literature. CJC-1295 without DAC (sometimes called Modified GRF 1-29) is a related but distinct compound with a different half-life profile; the two should not be conflated.

Considerations

Research-based concerns about sustained GH/IGF-1 elevation center on long-term effects that have not been characterized in extended human studies. Elevated IGF-1 is a known mitogen (a cell-growth promoter), and the theoretical implications of chronic elevation — including potential effects on insulin sensitivity and cell growth pathways — are topics of ongoing scientific discussion rather than resolved clinical questions. Injection site reactions, fluid retention, and transient hypoglycemia are considerations documented in GH secretagogue research. Individuals with acromegaly, active malignancy, or pre-existing endocrine disorders would face particular caution. As with all unapproved compounds in the peptide research space, the absence of Phase 3 human safety data means that long-term risk assessment relies substantially on inference from shorter-term or animal data. Clinician oversight including baseline and follow-up endocrine evaluation is essential.